Perspective Therapeutics, Inc. Common Stock (CATX)

Perspective Therapeutics Inc (CATX) reported strong Q2 2025 revenue, beating estimates by 84%, with a narrower-than-expected loss. The company advances its radiopharmaceutical pipeline, including [212Pb]VMT-α-NET for neuroendocrine tumors.

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, and anti-tumor activity.

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns.

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals.

CATX stock results show that Perspective Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Given its performance in 2024, there are very few stocks outperforming Nvidia this year. Here are three of them.